摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Acetoxymethyl-6-methyl-pyrazin | 86725-83-9

中文名称
——
中文别名
——
英文名称
2-Acetoxymethyl-6-methyl-pyrazin
英文别名
2-acetoxymethyl-6-methyl-pyrazine;(6-Methylpyrazin-2-yl)methyl acetate
2-Acetoxymethyl-6-methyl-pyrazin化学式
CAS
86725-83-9
化学式
C8H10N2O2
mdl
——
分子量
166.18
InChiKey
HWMSEKNMBIGOAM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    52.1
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BIS-AMINES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION<br/>[FR] BIS-AMINES, COMPOSITIONS ET UTILISATIONS ASSOCIÉES À L'INHIBITION DE CXCR4
    申请人:UNIV EMORY
    公开号:WO2017011517A1
    公开(公告)日:2017-01-19
    This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula (I), salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
    这项披露涉及此处披露的双胺化合物以及与CXCR4抑制相关的用途。在某些实施例中,该化合物具有式(I)的结构,其盐、衍生物和前药,其中A是桥接芳基或杂环基,R1和R2在此处进一步披露。在某些实施例中,披露考虑包含此处披露的化合物的药物组合物。在某些实施例中,该披露涉及通过向需要的对象施用此处披露的化合物的有效量来治疗或预防与CXCR4相关的疾病或状况的方法。
  • Bis-amines, compositions, and uses related to CXCR4 inhibition
    申请人:Emory University
    公开号:US11517565B2
    公开(公告)日:2022-12-06
    This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is an bridging aryl or heterocyclyl and R 1 and R 2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
    本公开涉及本文公开的双胺化合物以及与 CXCR4 抑制相关的用途。在某些实施方案中,化合物具有式 I、 其中,A 是桥接芳基或杂环基,R 1 和 R 2 在此进一步公开。在某些实施方案中,本公开考虑了包含本文公开的化合物的药物组合物。在某些实施方案中,本公开涉及通过向有需要的受试者施用有效量的本文公开的化合物来治疗或预防CXCR4相关疾病或病症的方法。
  • OHTA, AKIHIRO;IMAZEKI, AKIKO;ITOIGAWA, YOHKO;YAMADA, HIROKO;SUGA, CIEKO;T+, J. HETEROCYCL. CHEM., 1983, 20, N 2, 311-320
    作者:OHTA, AKIHIRO、IMAZEKI, AKIKO、ITOIGAWA, YOHKO、YAMADA, HIROKO、SUGA, CIEKO、T+
    DOI:——
    日期:——
  • Bis-amines, Compositions, and Uses Related to CXCR4 Inhibition
    申请人:Emory University
    公开号:US20200316040A1
    公开(公告)日:2020-10-08
    This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is an bridging aryl or heterocyclyl and R 1 and R 2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
  • Ohta, Akihiro; Imazeki, Akiko; Itoigawa, Yohko, Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 311 - 320
    作者:Ohta, Akihiro、Imazeki, Akiko、Itoigawa, Yohko、Yamada, Hiroko、Suga, Chieko、et al.
    DOI:——
    日期:——
查看更多